KRAS and non-small cell lung carcinoma: Preliminary results of the TROPION-Lung02 (NCT04526691) trial showed a notable activity of the combination of datopotomab deruxtecan (Dato-DXd)—a TROP2-directed ADC—plus pembrolizumab with or without platinum chemotherapy in advanced pretreated NSCLC [155]; however, only patients with KRAS mutations were eligible for the study, while other AGAs were considered exclusion criteria.